Vanda Pharmaceuticals | VNDA - Należności Handlowe





Należności Handlowe Zmiana Data
Acadia Pharmaceuticals USD 148.23M 8.79M 2025-12
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Akebia Therapeutics USD 47.03M 19.19M 2025-12
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Anika Therapeutics USD 29.33M 661K 2025-12
Arrowhead Research USD 218.87M 212.05M 2025-12
AstraZeneca USD 17.88B 1.17B 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Eli Lilly USD 21.18B 1.02B 2026-03
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Heron Therapeutics USD 89.59M 8.54M 2025-12
Insmed USD 140.86M 75.6M 2025-12
J&J USD 21.33B 3.72B 2025-12
Lexicon Pharmaceuticals USD 2.38M 50K 2025-12
Ligand Pharmaceuticals USD 58.1M 15.98M 2025-09
Merck USD 11.78B 345M 2025-12
Moderna USD 71M 113M 2026-03
Novartis USD 12.29B 3.3B 2025-12
Pfizer USD 16.17B 332M 2026-03
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 482M 85M 2026-03
Takeda JPY 757.92B 55.68B 2025-12
Teva Pharmaceutical Industries USD 3.39B 316M 2026-03
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12
Veracyte USD 50.11M 5.45M 2026-03